With the FDA approvals of several cell therapy products (Kymriah® and Yescarta®) and many more cell therapies progressing towards clinical trials, sourcing high-quality cellular materials has become a critical determinant of cell therapy development success. Particularly as allogeneic approaches to cell therapies become more feasible, access to donor cells that meet regulatory, quality, and quantity […]